Arcus Biosciences Inc
RCUS
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.82B
Close$
$-24.56
183.2% downside
Current Fair Value
183.2% downsideOvervalued by 183.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.82 Billion |
|---|---|
| Enterprise Value | $3.80 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.29 |
| Beta | 0.81 |
| Outstanding Shares | 126,100,000 |
Return
| Return on Equity | -97.41% |
|---|---|
| Return on Assets | -48.92% |
| Return on Invested Capital | -60.61% |
Valuation & Multiples
| P/E Ratio | -7.72 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 9.84 |
| Enterprise Value to Revenue | 32.47 |
| Enterprise Value to EBIT | -8.63 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.89
Average shareholder expectationRevenue Estimate
$21.98 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$-0.92
Average shareholder expectationRevenue Estimate
$12.03 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1283▼ 33.29% |
|---|---|
| Total Calls | 412,416▲ 18.58% |
| Total Puts | 52,900▼ 67.02% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 98.40%▼ 12.47% |
|---|---|
| Total Invested | $3.80B▲ 47.85% |
| Investors Holding | 235▲ 14.00% |
ESG Score
No data